Loading, Please Wait...
-- Forty Seven to Host Investor Event and Webcast on June 3, 2019 --
-- Forty Seven Management to Participate in MATTER Panel, The Current and Future Wave of Immuno-Oncology Therapies, on May 30, 2019 --
MENLO PARK, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that promising initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) will be presented in a poster discussion session at the 2019 ASCO Annual Meeting in Chicago, Illinois, May 31-June 4, 2019.
Presentation Title: The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date & Time: Monday, June 3, 2019 from 4:30 p.m. – 6:00 p.m. CT (5:30 p.m. – 7:00 p.m. ET)
Abstract Number: 7009
Location: Poster Board #384, Hall A, McCormick Place
The accepted abstract is now available online on the ASCO website: https://iplanner.asco.org.
Forty Seven’s Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of AML and MDS is funded in part by a research grant awarded by the California Institute for Regenerative Medicine (CIRM).
Investor Event and Webcast Information
Forty Seven will host an investor event on Monday, June 3, 2019 beginning at 6:30 p.m. CT (7:30 p.m. ET) in Chicago to review the initial clinical data presented at ASCO for 5F9. The event will be webcast live and can be accessed under “Events & Presentations” in the Investors section of the Forty Seven website at www.fortyseveninc.com. A replay of the webcast will be available approximately two hours after the event and will be available for 30 days following the event.
MATTER Event and Webcast Information
Forty Seven’s Chief Executive Officer, Mark McCamish, M.D., Ph.D., and Founder and Vice President, Clinical Development, Mark Chao, M.D., Ph.D., will present on the Company’s approach to drug development at an event hosted by MATTER on Thursday, May 30, 2019 beginning at 6:00 p.m. CT (7:00 p.m. ET). The event, titled “The Current and Future Wave of Immuno-oncology Therapies,” will be webcast live and can be accessed under “Events & Presentations” in the Investors section of the Forty Seven website at www.fortyseveninc.com.
About Forty Seven Inc.:
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven’s lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in multiple clinical studies in patients with solid tumors, acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin’s lymphoma, ovarian cancer and colorectal carcinoma.
For more information please visit www.fortyseveninc.com or contact email@example.com.
For journalist enquiries please contact Sarah Plumridge at firstname.lastname@example.org or phone (312) 506-5219.
For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at email@example.com or phone (212) 362-1200.